Search the Newsreel

Optima Health lifts revenue and margins as PAM acquisition strengthens UK occupational health position

Option Care Health, Inc. (NASDAQ:OPCH) Given Average Rating of "Moderate Buy" by Brokerages

Option Care Health, Inc. (NASDAQ:OPCH) has received a consensus "Moderate Buy" rating from 14 analysts, with seven rating it a "buy" and seven a "hold." The average 12-month price target is $29.92, surpassing its current share price of $23.94, despite some recent analyst downgrades …

Optimum Communications (NYSE:OPTU) Stock Gets Fair Value Trim As Analysts Split On Risk

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The latest update for Optimum Communications focuses on a reduced fair value estimate, shifting …

Analysten haben eine Finanzbewertung zum Bericht der Jenoptik AG (ETR:JEN) für das zweite Quartal abgegeben

Dimensional Fund Advisors LP Sells 100,721 Shares of Optical Cable Corporation $OCC

Dimensional Fund Advisors LP reduced its stake in Optical Cable Corporation (NASDAQ:OCC) by 37.5%, selling over 100,000 shares but still retaining a significant holding. This comes as the company's CFO also sold a portion of her shares. Despite a recent 7.0% stock price increase, …

Wall Street Zen Upgrades Syntec Optics (NASDAQ:OPTX) to "Hold"

Aksh Optifibre reports consolidated net profit of Rs 4.71 crore in the June 2026 quarter

Top Optimi Health (OPTH) Competitors 2026

This article analyzes Optimi Health (OPTH) against its main competitors in the pharmaceuticals industry: Rafael (RFL), ImmuCell (ICCC), Cognition Therapeutics (CGTX), PolyPid (PYPD), and RF Acquisition Corp II (RFAI). The comparison is based on factors such as profitability, valuation, earnings, analyst recommendations, institutional ownership, …

Optimi Health (OPTH) Stock Chart and Price History 2026

OptimizeRx (OPRX) Stock Grapples With Revenue Slump Despite Margin Progress

Optimi Health Corp. Establishes US$100 Million Discretionary Equity Line of Credit with Seven Knots

Optimi Health Corp. has secured a discretionary equity line of credit of up to US$100 million with Seven Knots, LLC, providing flexible capital for its psychedelic pharmaceutical operations. The agreement allows Optimi to sell common shares to Seven Knots at its discretion, with individual …

Optimi Health (OPTH) raises $20.7M, posts larger loss and builds cash buffer

Optimi Health (OPTH) reported a wider net loss of $5.6 million for the nine months ending June 30, 2026, despite securing $20.7 million in gross proceeds from a Nasdaq public offering. Revenue decreased to $239,700 from $490,330 in the prior year, attributed to Australian …

Optimi Health (OPTH) secures US$100M equity line with convertible note sweeteners

Optimi Health Corp. (OPTH) has secured a US$100 million discretionary equity line of credit with Seven Knots, LLC, allowing Optimi to sell common shares over time at its discretion. As part of the agreement, Optimi issued a US$1.5 million unsecured, non-interest-bearing convertible note and …

Optimi Health Corp. Announces Up to US$100 Million Equity Line of Credit with Seven Knots

Durable Capital discloses 6.16M Option Care shares in 13G/A filing (OPCH)

Durable Capital Partners has filed an amended ownership report for Option Care Health, Inc. common stock, revealing a 3.9% stake. Durable Capital Master Fund LP directly holds 6,163,722 shares, with Durable Capital Partners acting as the investment adviser having sole voting and dispositive power …

OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital

Kennedy Capital Management LLC has reported a beneficial ownership of 1,248,899 shares of OptimizeRx Corp (OPRX) common stock, representing a 6.7% stake. The firm, based in St. Louis, Missouri, holds sole voting and dispositive power over these shares, establishing itself as a significant institutional …

OPTX Swings to Earnings in Q2 on Defense, Communications Growth

Shares of Syntec Optics Holdings, Inc. OPTX have gained 12.3% since the company reported its earnings for the quarter ended June 30, 2026, outperforming the S&P 500 index's 0.3% decline over the same period. Over the past month, Syntec Optics shares have advanced 7.9% …

Aksh Optifibre Posts Q1 Profit Amidst CIRP, Auditors Raise Concerns

Sei Investments Co. Acquires Shares of 91,364 Optical Cable Corporation $OCC

Sei Investments Co. has acquired 91,364 shares of Optical Cable Corporation (NASDAQ:OCC), valued at approximately $754,000, representing a 1.03% stake. Despite strong quarterly earnings where Optical Cable reported $0.12 EPS, a significant improvement from a loss of $0.09 per share a year ago, analyst …

China Electronics Optics Valley Union Warns of RMB96 Million Interim Loss Amid Property Market Weakness

Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX

Renaissance Technologies LLC significantly increased its stake in OptimizeRx Corp. (NASDAQ:OPRX) by 633.2% in the first quarter, now holding 216,856 shares valued at $1.36 million. OptimizeRx reported strong Q2 earnings, beating analyst estimates with $0.16 EPS and $20.5 million in revenue, and maintained its …

Citizens raises OptimizeRx stock price target on macro stability

Citizens has increased its price target for OptimizeRx (NASDAQ:OPRX) to $11.00 from $9.00, maintaining a Market Outperform rating. This adjustment is based on a stabilizing macro environment, the potential return of a large customer, and momentum in mid-tier biopharma. The new target reflects an …

Jenoptik AG (JNPKF) (Q2 2026) Earnings Call Highlights: Record Orders and Raised Guidance ...

This article first appeared on GuruFocus. Revenue: Group revenue up 1% year-on-year in H1 2026; excluding currency effects, growth was close to 3%. Order Intake: Group order intake up more than 50% year-on-year in H1 2026. Book-to-Bill Ratio: H1 book-to-bill ratio rose sharply to …

Precision Optics (POCI) CFO acquires 1,257 shares via stock compensation plan

Precision Optics Corporation, Inc. CFO Wayne M. Coll acquired 1,257 shares of common stock on June 30, 2026, at $4.972 per share as a grant/award. This transaction is part of an Employment Agreement allowing up to $25,000 per year of compensation to be paid …

OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold

OptimizeRx (OPRX) reported a significant revenue decline of 21% year-to-date and 30% in Q2 2026, primarily due to the wind-down of a low-margin managed service program and the loss of revenue from a key customer. Despite this, the company improved its gross margin by …

Stifel cuts OptimizeRx stock price target on revenue headwinds

Stifel has lowered its price target for OptimizeRx (NASDAQ: OPRX) to $12 from $14, while maintaining a Buy rating, due to significant revenue headwinds. The company reported a 30% year-over-year revenue decline in Q2 2026, though adjusted earnings per share exceeded expectations. OptimizeRx reiterated …

Arts Optical Sets Board Meeting to Approve 2026 Interim Results and Dividend

MetaOptics Deploys Metalens Direct Laser Writer at Stanford Nano Facility to Drive U.S. Expansion

OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth

OptimizeRx has announced significant finance leadership appointments, effective January 1, 2027, as part of its succession planning. Andy D’Silva will take over as Chief Financial Officer, succeeding Ed Stelmakh, who will transition to a Strategic Advisor role. Heather Favazza has been appointed Chief Accounting …

OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ...

OptimizeRx Corp (OPRX) reported a 30% year-over-year revenue decrease in Q2 2026, reaching $20.5 million, with adjusted EBITDA falling to $4.1 million. Despite these revenue headwinds, the company exceeded consensus expectations, driven by strong growth in AI-enabled software and product innovations. OptimizeRx reaffirmed its …

Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip

OptimizeRx Corp. reported Q2 2026 adjusted earnings of $0.16 per share, surpassing the $0.10 consensus, and revenue of $20.5 million, above the $20.19 million expectation. Despite beating profit views, the stock slipped after hours due to a 30% year-over-year revenue decline and continued pressure …

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates

OptimizeRx Corp. (OPRX) exceeded Q2 earnings and revenue estimates, reporting $0.16 per share against an expected $0.11, and revenues of $20.5 million, slightly above the consensus. Despite these positive results, the company's shares have underperformed the S&P 500 this year, with a Zacks Rank …

OptimizeRx Refinances Debt With $35M Facility, Pays Down $8.3M